Strategies for Stakeholders: Navigating the US$15.6 Billion Cell Therapy Manufacturing Market by 2033 | Insights by FMI Inc.

Anticipated to attain a valuation of approximately US$ 4,134.48 million in 2023, the global market for Cell Therapy Manufacturing is on a trajectory of substantial growth. This expansion is projected to continue at a Compound Annual Growth Rate (CAGR) of 14.2% spanning from 2023 to 2033. By the culmination of 2033, it is expected that the market will surge to an estimated valuation of around US$ 15,634.67 million. Notably, autologous cell therapy manufacturing spearheads the global market, boasting a significant share of about 56.0% as of 2021.

Cell therapies are utilized widely to treat viral infections, cancer, hemoglobinopathies, and hereditary immunological disorders. The introduction of reagents and closed-system automated equipment for the manufacturing of cellular therapies is an outcome of the increasing research activities in the field of such therapies.

A decentralized manufacturing model for clinical trials in cell therapies engaging multiple sites is being favored across the globe. Such instances advocate the treatment of patients using cells, which are produced by utilizing automated equipment at each participating center by considering a single, centrally held investigational new drug application (IND).

Explore the Booming Cell Therapy Manufacturing Market with Our Sample Report! @
https://www.futuremarketinsights.com/reports/sample/rep-gb-15536

Many academic centres are nowadays investing in the development of such automated devices for point-of-care manufacturing and engagement in decentralized multi--center Clinical Trials. The global cell therapy manufacturing market would thus observe a boom in the next decade. Besides, the introduction of novel therapies licensed by regulatory bodies for targeted therapeutic approach would further propel the overall growth in the market during the projected period.

Key Takeaways from Market Study

-By source, the autologous segment held a global market share of about 0% in 2021.
-Based on indication, the cancer segment held nearly 0% in 2021 in the cell therapy manufacturing market.
-In terms of purpose, the clinical segment accounted for around 0% of the global market share in 2021.
-Injectable route of administration of cell therapies generated a global market share of around 0% in 2021.
-By cell type, the hematopoietic stem cells (HSC) segment held a share of around 0% in the global cell therapy manufacturing market in 2021.
-By end use, the hospital settings category generated a share of around 1% in 2021 in the global cell therapy manufacturing market.
-China held a share of around 2% in 2021 in the East Asia cell therapy manufacturing market.

"Increasing number of research activities by key companies to reduce risks and get ready for a highly productive future are anticipated to drive the market. Besides, they are striving to develop innovative technologies that can assist investigators in automating their processes for gaining success in the future," says an analyst of Future Market Insights.

Competitive Landscape: Cell Therapy Manufacturing Market

Key players in the cell therapy manufacturing market are focusing on R&D activities to initiate regenerative medicine manufacturing. Moreover, they are promoting commercial manufacturing for their clients by offering novel solutions to cell therapy developers.

For instance,

-In March 2022, Thermo Fisher Scientific presented a new large-volume electroporation system, the purpose of which is to simplify cell therapy development. The company aims to simplify transition from clinical development to commercial manufacturing among Cell Therapy Developers.
-Charles River Laboratories' Memphis plant became the first CDMO in North America to manufacture commercial allogeneic cell therapies after receiving European Medicines Agency (EMA) approval in August 2022.

Get Exclusive Insights on Cell Therapy Manufacturing Market

Future Market Insights offers a unique perspective and actionable insights on the cell therapy manufacturing market in its latest study, presenting a historical demand assessment of 2012 - 2021 and projections for 2022 - 2032. The global cell therapy manufacturing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Key Players:

-Merck KGaA
-Avantor, Inc.
-Cell Therapies Pty Ltd
-Thermo Fisher Scientific
-Charles River Laboratories
-Catalent, Inc
-Bio-Techne
vCytiva
-Lonza
-The Discovery Labs
-BIOCENTRIQ
-FUJIFILM Diosynth Biotechnologies
-Novartis AG
-Bristol-Myers Squibb Company
-Gilead Sciences, Inc.
-WuXi AppTec.
-OXGENE
-Pharmaron
-Aldevron
-FLODESIGN SONICS
-Exothera

Get Ahead with Comprehensive Information - Purchase The Report Today!
https://www.futuremarketinsights.com/checkout/15536

Key Segments Covered in Cell Therapy Manufacturing Industry

By Source:

-Autologous
-Allogenic

By Indication:

-HIV
-Autoimmune Disorders
-Immune Deficiencies
-Cancer
-Neurological Disorders

By Manufacturing Purpose:

-Clinical
-Commercial
-Pre-clinical

By Route of Administration:

-Topical
-Injectable
-Infusion
-Implantable Bio-Scaffold

By Cell Type:

-Hematopoietic (Blood-Forming) Stem Cells (HSC)
-Skeletal Muscle Stem Cells
-Mesenchymal Stem Cells
-Lymphocytes
-Dendritic Cells
-Pancreatic Islet Cells
-CAR-T Cells

By End User:

-Hospital Settings
-Intensive Outpatient Treatment Centers
-Academic and Research Institutes
-Specialty Clinics

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Read the Complete Analysis Here: 
https://www.futuremarketinsights.com/reports/cell-therapy-manufacturing-market

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

This release was published on openPR.